LASA Supergenerics LTD

Lasa Supergenerics Ltd (LASA) is a micro-cap Healthcare company valued at ₹26 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Lasa Supergenerics Ltd last traded at ₹5.1, down 4.14% on the day.

Recent developments

2026-06-30: The company reported a net loss of ₹4 crore for the latest quarter, following a net loss of ₹6 crore in the previous quarter. 2026-03-31: The company reported a net loss of ₹4 crore for the quarter ending March 2026, following a net loss of ₹3 crore in the previous quarter.

Financial performance

The company's business is deteriorating, with annual revenue falling 82.3% and annual net profit turning into a loss that widened from ₹15 crore to ₹34 crore. The latest quarter shows revenue plummeted 93.9% and the net loss narrowed from ₹21 crore to ₹4 crore.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 0.57 times book value.

Things to watch

The company has reported a net loss of ₹34 crore for the latest fiscal year, with the net loss widening from ₹15 crore to ₹34 crore. The net profit margin is -135.6%, down 125.0 percentage points from the prior year. The company's return on equity is -68.7% and return on capital employed is -57.6%.

Where it stands

The company's financial performance has worsened, with annual revenue falling 82.3% and annual net profit turning into a loss that widened from ₹15 crore to ₹34 crore. The latest quarter shows revenue plummeted 93.9% and the net loss narrowed from ₹21 crore to ₹4 crore.

Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.